ZURICH, Dec 23 (Reuters) - Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) outside the United States, it said on Monday.
Roche will make an upfront payment of $750 million in cash and $400 million worth in equity at closing for Sarepta’s investigational micro-dystrophin gene therapy SRP-9001, it said in a statement on Monday.
Sarepta is eligible to receive up to $1.7 billion in regulatory and sales milestones, plus royalties on net sales, Roche said.
Reporting by Silke Koltrowitz Editing by Tassilo Hummel
Our Standards: The Thomson Reuters Trust Principles.